DR. BARRY S. COLLER, M.D.
Osteopathic Medicine at York Ave, New York, NY
License number
New York 110307
Category
Osteopathic Medicine
Type
Hematology
Address
Address
1230 York Ave, New York, NY 10021
Phone
(212) 327-7490
(212) 327-7493 (Fax)
(212) 327-7493 (Fax)
Personal information
See more information about BARRY S. COLLER at radaris.comName
Address
Phone
1160 Park Ave #6A, New York, NY 10128
1160 Park Ave APT 6A, New York, NY 10128
New York, NY
1160 Park Ave #6A, New York, NY 10128
1160 Park, New York, NY 10128
Professional information
See more information about BARRY S. COLLER at trustoria.com
Dr. Barry S Coller, New York NY - MD (Doctor of Medicine)
Dr. Barry S Coller, New York NY - MD (Doctor of Medicine)
Specialties:
Hematology, Hematopathology
Address:
BARRY SPENCER COLLER MD
1230 York Ave SUITE 309, New York 10065
(212) 327-7490 (Phone), (212) 327-7493 (Fax)
1230 York Ave SUITE 309, New York 10065
(212) 327-7490 (Phone), (212) 327-7493 (Fax)
Certifications:
Hematology, 1974, Hematology & Pathology, 1975, Internal Medicine, 1973
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
New York University
Graduated: 1970
Bellevue Hospital Center
New York University
Graduated: 1970
Bellevue Hospital Center
Barry Spencer Coller, New York NY
Barry Spencer Coller, New York NY
Specialties:
Internal Medicine, Hematology, Hematology
Work:
Rockefeller University Hospital
1230 York Ave, New York, NY 10065
1230 York Ave, New York, NY 10065
Education:
New York University (1970)
Methods For Measuring Platelet Reactivity Of Patients That Have Received Drug Eluting Stents
Methods For Measuring Platelet Reactivity Of Patients That Have Received Drug Eluting Stents
US Patent:
2007024, Oct 18, 2007
Filed:
May 1, 2007
Appl. No.:
11/742684
Inventors:
Barry Coller - New York NY, US
Dennis Durbin - Solana Beach CA, US
Dennis Durbin - Solana Beach CA, US
International Classification:
G01N 33/50
US Classification:
436503000
Abstract:
A method is providing for measuring platelet reactivity of a PCI patient that has a (DES). A blood sample is obtained from the patient. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the mixture. The absence of agglutination indicates that the patient has reduced ability to form platelet thrombi.
Methods For Measuring Platelet Reactivity Of Individuals Treated With Drug Eluting Stents
Methods For Measuring Platelet Reactivity Of Individuals Treated With Drug Eluting Stents
US Patent:
2010018, Jul 22, 2010
Filed:
May 1, 2008
Appl. No.:
12/598581
Inventors:
Barry Coller - New York NY, US
Dennis Durbin - Solana Beach CA, US
Dennis Durbin - Solana Beach CA, US
International Classification:
G01N 33/53
US Classification:
435 71
Abstract:
A method is provided for measuring inhibition of platelet reactivity in an individual treated with a drug-eluting stent (DES). First, a blood sample is obtained from an individual treated with a DES and a P2Y12 antagonist. The blood sample is then mixed with particles comprising an attached GPIIb/IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1). The mixture is incubated under conditions suitable for agglutinating particles, and platelet-mediated agglutination is assessed in the mixture. The absence or reduction of agglutination indicates that the individual treated with a DES has reduced platelet reactivity. Also provided is a kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist that includes a GPIIb/IIIa receptor ligand immobilized on a particle, adenosine diphosphate (ADP), prostaglandin E1 (PGE1), an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation.
Controlled Platelet Activation To Monitor Therapy Of Adp Antagonists
Controlled Platelet Activation To Monitor Therapy Of Adp Antagonists
US Patent:
2011008, Apr 7, 2011
Filed:
Nov 10, 2010
Appl. No.:
12/943413
Inventors:
Barry S. COLLER - New York NY, US
Dennis Durbin - Solana Beach CA, US
Dennis Durbin - Solana Beach CA, US
Assignee:
ACCUMETRICS, INC. - SAN DIEGO CA
International Classification:
G01N 33/53
US Classification:
435 71, 436 63
Abstract:
A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi.
Methods Of Treating Sickle Cell Disease
Methods Of Treating Sickle Cell Disease
US Patent:
2005011, May 26, 2005
Filed:
Nov 3, 2004
Appl. No.:
10/980496
Inventors:
Paul Frenette - New York NY, US
Barry Coller - New York NY, US
Aslihan Turhan - Boston MA, US
Barry Coller - New York NY, US
Aslihan Turhan - Boston MA, US
International Classification:
A61K039/395
US Classification:
424144100
Abstract:
The present invention relates to methods of treating sickle cell disease comprising reducing, in a subject in need of such treatment, the adherence between sickle RBCs and leukocytes. It is based, at least in part, on the discovery that leukocytes play a direct role in the initiation of venular occlusion. The present invention further provides for methods for identifying agents which decrease SS-RBC/leukocyte adherence and for animal models which may be used to further elucidate the mechanism of vaso-occlusion in sickle cell crises.
Controlled Platelet Activation To Monitor Therapy Of Adp Antagonists
Controlled Platelet Activation To Monitor Therapy Of Adp Antagonists
US Patent:
7790362, Sep 7, 2010
Filed:
Jul 6, 2004
Appl. No.:
10/886155
Inventors:
Barry S. Coller - New York NY, US
Dennis Durbin - Solana Beach CA, US
Dennis Durbin - Solana Beach CA, US
Assignee:
Accumetrics, Inc. - San Diego CA
International Classification:
C12Q 1/00
US Classification:
435 4
Abstract:
A method is provided of determining whether an individual has reduced ability to form platelet thrombi. An ADP platelet activator and one or platelet inhibitors are provided. At least one of the platelet inhibitors is Prostaglandin E1 (PGE1). An alternate signal transduction pathway is produced. A final concentration of ADP is 2 to 35 μM and a final concentration of PGE1 is 2 to 30 nM, preferably 20 to 25 nM.
Platelet Blockade Assay
Platelet Blockade Assay
US Patent:
5854005, Dec 29, 1998
Filed:
Nov 20, 1996
Appl. No.:
8/754773
Inventors:
Barry S. Coller - New York NY
Assignee:
Mount Sinai School of Medicine - New York NY
International Classification:
G01N 33546, G01N 33552
US Classification:
435 721
Abstract:
The present invention is an assay for determining glycoprotein IIb/IIIa receptor blockade in whole blood. Agglutinization of small polymeric beads coated with a glycoprotein IIb/IIIa ligand such as fibrinogen results when the beads are contacted with whole blood containing platelets with glycoprotein IIb/IIIa receptors that are not blocked. Failure to agglutinate indicates that blockade of the GPIIb/IIIa receptors has been achieved. In a preferred embodiment, the addition of a thrombin receptor activator results in an assay that is rapid and convenient enough to be performed at the bedside and that results in agglutination of the small polymeric beads within a convenient, known period of time if the glycoprotein IIb/IIIa receptors are not blocked.
Alpha-Iib-Beta-3 Inhibitors And Uses Thereof
Alpha-Iib-Beta-3 Inhibitors And Uses Thereof
US Patent:
8173661, May 8, 2012
Filed:
Nov 8, 2007
Appl. No.:
12/514286
Inventors:
Robert Blue - Panama City FL, US
Barry S. Coller - New York NY, US
Barry S. Coller - New York NY, US
Assignee:
The Rockefeller University - New York NY
International Classification:
A01N 43/90, A61K 31/519, C07D 471/00, C07D 487/00, C07D 491/00
US Classification:
5142593, 544255
Abstract:
The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention also relates to methods for screening compounds and compositions useful for inhibiting or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.
Organic Compounds
Organic Compounds
US Patent:
2012019, Jul 26, 2012
Filed:
Apr 6, 2012
Appl. No.:
13/441412
Inventors:
Robert Blue - New York NY, US
Barry S. Coller - New York NY, US
Barry S. Coller - New York NY, US
International Classification:
A61K 31/727, A61P 7/02, A61K 31/519
US Classification:
514 56, 51425216
Abstract:
The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention also relates to methods for screening compounds and compositions useful for inhibiting or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.